Generic Versus Branded Atorvastatin: A Single-Center Comparative Analysis of Clinical Effectiveness and Post-Delisting Cost Savings in Saudi Arabia
Abdulmajeed Hassan Jaafari, Abdulaziz Sami Al-Shwairkh, Miteb A. Alanazi, Abdullah M. Alhammad, Yazed Alruthia · 2026
Read Generic Versus Branded Atorvastatin: A Single-Center Comparative Analysis of Clinical Effectiveness and Post-Delisting Cost Savings in Saudi Arabia by Abdulmajeed Hassan Jaafari, Abdulaziz Sami Al-Shwairkh, Miteb A. Alanazi, Abdullah M. Alhammad, Yazed Alruthia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13606422.txt.
Description
Abdulmajeed Jaafari and four co-authors compare, in 2026 work, a generic cholesterol drug with its branded twin at one Saudi hospital. Statin drugs cut harmful fats in the blood, and cheap generic forms are now wide spread. Doubts about whether they work as well have lingered, so the team checked both care results and cost.
Nearly three hundred patients took one form or the other over a ten-year span. The generic form cut the key harmful fat by a bit more, but the gap was too small to count as firm. Cost models then projected large yearly savings for the land as a whole if the generic form is used. Those savings held across all scenes the team tried. They back wider generic use.
Catalog record
| CREATOR | Abdulmajeed Hassan Jaafari, Abdulaziz Sami Al-Shwairkh, Miteb A. Alanazi, Abdullah M. Alhammad, Yazed Alruthia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |